![]() |
| Site Navigation | Chemotherapy - Vinblastine |
|
|
| Vinblastine (common brand names velban,
velsar, velbe) is a chemotherapy agent used in the treatment of Hodgkin's
Lymphoma / Disease. It is more often than not
given in conjunction with other chemotherapy agents in a multidrug regimen. An
antineoplastic, vinblastine interferes with the growth of cancer cells - it does this by
inhibiting microtubule production on cells. It is in the vinca alkaloid family of drugs
which includes vincristine, a very different drug,
used to treat some forms of non-Hodgkin's lymphoma.
Both vinblastine and vincristine are used in the Stanford V
regimen whereas vinblastine alone is used in ABVD. Originally
derived from the Madagascar periwinkle plant Catharanthus roseus. Before taking this medicine: Inform the doctor if you have had kidney,
liver, or lung disease. It should not be taken while pregnant and not while breast feeding
without your doctors' advise. Some of the Regimens using Vinblastine:
Vinblastine Reference Links:
Manufacturer:
Disclaimer: This information is general in nature. Please consult with a doctor or the literature provided with the drugs if you need specific information on a drug. The author is not responsible for missing or inaccurate information and the reader assumes full responsibility for their actions. As always, please consult with medical personnel before undertaking any medical treatment. For more information on Hodgkin's Disease, please see the following pages: :
For more information on Non-Hodgkin's Lymphoma, please see the following pages: :
The Main Page - gateway to support and more This page is a work in progress - if you have more complete information, references, or other information please contact the author. The author is not in the medical field and does not warrant the correctness of the material on this page or the sites linked - please take online information and consult with your own medical team to make informed decisions. Copyright © 1998-2005 Lymphoma Information
Network - All Rights Reserved |
||